-+ 0.00%
-+ 0.00%
-+ 0.00%

CERVOMED ANNOUNCES INITIAL RESULTS FROM THE PHASE 2A CLINICAL TRIAL OF NEFLAMAPIMOD IN NONFLUENT VARIANT PRIMARY PROGRESSIVE APHASIA (NFVPPA) HAVE BEEN ACCEPTED AS A LATE-BREAKING ORAL SESSION AT ISFTD 2026

Reuters·09/10/2026 11:30:00

Please log in to view news